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A “Medication Profile,” the information about the medicines a person is using and has used, is a core part of many electronic health
record systems and summaries. However, there is little objective research into the data elements that the profile should contain
to support the uses it must serve. With the increasing emphasis on secondary uses of electronic health information, as well as
supporting the requirements to support direct to patient care, the Medication Profile should also support the requirements from
clinical research. However, there is little, if any, description of these available. This paper describes an analysis of a set of study
eligibility criteria that was undertaken to investigate which medication-related data elements would be required to support two
clinical research use cases: the parameters to query a patient’s Medication Profile to assess their suitability for entry into a trial
(patient recruitment) and the parameters to query a set of Medication Profiles in a data warehouse to assess whether the eligibility
criteria as described would yield a reasonable cohort of patients as potential subjects (protocol feasibility).Thesemedication-related
data elements then become information requirements that a Medication Profile should ideally meet, in order to be able to support
these two uses in the clinical research domain.
1. Introduction
As part of a larger requirements gathering exercise for the in-
depth analysis of the content needed in an ideal Medication
Profile from both direct to patient healthcare and clinical
research, requirements from two of the processes in clinical
research domain were studied. This paper focuses on the
medication information requirements to support protocol
feasibility and patient recruitment studies. Requirements
from the other contexts will be published in due course,
together with a larger set of recommendations.
The provision of accurate information about the medi-
cines that a patient is using now and has used in the past is
extremely important both for the provision of direct patient
care and also for the so-called “secondary uses” of informa-
tion for research. This information is often termed the
patient’s “Medication Profile”; however there is little if any
consensus as to what a Medication Profile should contain [1–
5].
Subjects are selected as suitable for recruitment into a
clinical study based on eligibility criteria which are formally
documented as part of the protocol for the study. Finding
suitable subjects is known to be difficult [6, 7], and success
in recruitment is variable [8]. Various strategies are being
developed to support recruitment, including design and
deployment of systems for protocol feasibility studies and
subject identification and recruitment [9]. These use the
content of prospective or actual eligibility criteria as queries
against a patient data warehouse to retrieve either numbers
of the likely to be eligible patients (for feasibility testing) or
individual patients (for possible recruitment).
There has been little analysis of the content of eligibility
criteria and none specifically on their medication-related
content. van Spall et al. [10] undertook a systematic review of
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the description of exclusion criteria (only) in published ran-
domised controlled trials; 54.1% of the trials examined had
“medication-related reasons” for exclusionmeaning that over
half of all trials studied required at least some medication-
related information for eligibility assessment.Weng et al. con-
ducted an examination of eligibility criteria specifically for
their computability to support clinical research and focused
on the semantic structuring of the criteria [11], rather than on
their clinical content. Ross et al. [12] conducted an analysis
to characterise eligibility criteria into three categories, one of
which was “a treatment or intervention on the participant,”
which is presumed to include medication, and to quantify
their patterns and the complexity of these patterns.
The aim of this work was therefore to analyse a set of
study eligibility criteria and to specifically investigate in detail
the medication-related data elements which could be used as
parameters to query a patient’s Medication Profile to assess
their suitability for entry into a trial (patient recruitment)
or to query a set of Medication Profiles in a data warehouse
to assess whether the eligibility criteria as described would
yield a reasonable cohort of patients as potential subjects
(protocol feasibility).Thesemedication-related data elements
then become information requirements that a Medication
Profile should ideally meet, in order to be able to support
these two uses in the clinical research domain.
A subsidiary aim was to have some sense of the value, in
terms of frequency of use, of each of these data elements, such
that an assessment of their importance for the particular use
case can be made: if a parameter is used in many eligibility
criteria, the value of its presence in the Medication Profile is
high and vice versa.
2. Method
The analysis studied eligibility criteria from 41 clinical studies
conducted in Europe by nine different pharmaceutical com-
panies provided to the EHR4CR project [13] specifically for
use in protocol feasibility and patient recruitment studies.
This set of 41 trials had been selected from the total of studies
in progress at the EHR4CR Pilot Sites as being representative
of clinical studies currently conducted in the domain; the
selection was made by the EHR4CR EFPIA partners. There
were 1112 individual eligibility criteria from these studies,
although there was considerable variability in what each
trial considered to be a single eligibility criterion. For some
studies, a single criterion might contain a number of related
parameters each of which must be satisfied, whereas in other
studies each parameter was detailed as a separate criterion
to be satisfied. Because the investigation was seeking a
qualitative understanding of the requirements that eligibility
criteria place on the Medication Profile compared to a truly
quantitative measure, no attempt was made to normalise the
pattern of eligibility criteria such that each described one and
only one parameter; the eligibility criteria have been used and
counted exactly as they were supplied by their authors.
Each of the eligibility criteria was examined and those
whose parameter(s) involved medication information were
identified for further detailed study, including categorisation.
Medication Profile information has twomain parts: the iden-
tification of the medication(s) themselves and information
about their use in the patient, the dosage instructions; both
of these aspects were examined in more detail to elicit
requirements. Eligibility criteria describing adverse events to
medication occurring during the study (i.e., after a subject has
been recruited into the trial) were not included for detailed
evaluation (e.g., “any other hemorrhage/bleeding event >
CTCAE Grade 3 within 4 weeks of first dose of study drug”).
However, eligibility criteria that described adverse events to
medication that had occurred prior to the study and which
therefore might be expected to be documented in a patient’s
Medication Profile were identified and evaluated.
To provide some comparison to the medication infor-
mation based data elements, eligibility criteria whose data
element(s) involved laboratory test information were also
identified. Laboratory test information was defined as bio-
chemistry and haematology tests only; observables such as
blood pressure measurement, pathology, and microbiology
information were not included. Laboratory test information
was chosen as a comparator for medication information as
like medication information, it is highly structured with little
additional free text and is similarly stored in patient records.
3. Results
Of the 1112 eligibility criteria, therewere 201 thatmade a direct
reference tomedication that a potential subjectmay be taking
or may have taken.
In addition, therewere 79 eligibility criteria that described
medication-related information (allergy to medication and
adverse events from medication administration) that should
be available from an extended Medication Profile or that
could be queried by inference.
The number of eligibility criteria that involved laboratory
test information was 99; 39 were inclusion criteria and 60
were exclusion criteria.
4. Categorisation
The201 eligibility criteria containing reference tomedication-
related data elements were examined in detail and categorised
on the basis of whether they referred to current or past med-
ication use and whether they referred to medication infor-
mation use in context of a diagnosis, to use ofmedication that
was a study agent in a previous study, or to a medication fail-
ure (Figure 1).
“Current medication use” is defined as those eligibility
criteria that identify a medication (or group of medications
which might be defined by therapeutic category or by shared
indication) being taken by a patient/potential subject at the
time of recruitment into a study using words and were iden-
tified by phrases such as “(current) use of ” or “concomitant
administration of.”The large majority of these were exclusion
criteria with just 2 being inclusion criteria.
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Figure 1: Graph showing the initial categorisation of medication-
based eligibility criteria.
Example:
“Currently on any medication to treat high blood pres-
sure.”
Included in the “current medication use” category are those
eligibility criteria where there was some indication of the
timing of the medication administration in relation to the
current point in time or to a particular point in the study such
as randomisation, for which it is likely that the medication
would (still) be used “in the present.”
Example:
“Treatment with oral neuroleptics within 4 weeks prior
to the screening visit.”
“Past medication use” is the category of eligibility criteria that
describe amedication (or group ofmedications) that has been
taken in the past and is no longer being taken (words and
phrases such as “prior administration or” or “history of ”).
Some eligibility criteria were not explicit in their reference to
past medication use, for example, the criterion “at least one
but not more than 2 cytotoxic chemotherapy regimens for
metastatic castration-resistant prostate cancer”; this implies
that the chemotherapy must have happened previously to
“now” and would therefore be recorded as “past.” The “past
medication use” criteria were split with two-thirds being
exclusion criteria and one-third being inclusion criteria.
Example:
“History of prior exposure to carisbamate.”
The set of eligibility criteria described as “Diagnosis +Medica-
tion” are those where the primary criterion is that the subject
has the condition/symptom described (a “diagnosis”) with a
supplementary qualification identifying a medication. The
subject must have both the condition and symptom (diagno-
sis) and be using or have used the treatingmedication to fulfil
the criterion.
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Detailed analysis of the medication information-identifying medications
Figure 2: Graph of the various ways to identify medications in eli-
gibility criteria.
Example:
“Cardiac arrhythmias requiring anti-arrhythmic ther-
apy.”
“Prior study medication” is the category of eligibility criteria
which describe the use by a patient of a study agent in a pre-
vious study; the overwhelming majority (35) was exclusion
criteria, but there were 3 that were inclusion criteria (such
that the patient would be eligible as a subject for a “follow-
on trial”).
Example:
“Investigational drug therapy outside of this trial during
or within 4 weeks of study entry.”
There were 10 eligibility criteria that concerned “treatment
failure” which was recognised by phrases such as “inadequate
response to,” “resistance/resistant to,” and “relapse after”; with
just one exception these were all inclusion criteria (Figure 2).
Example:
“History of inadequate response to at least 1 AED
. . . .”(where AED = anti-epileptic drug).
Only 10 of the 201 eligibility criteria named a specific medi-
cation; all the others used a class description referring to char-
acteristics or use of the medicines in that class.
Medications were described on the basis of their categori-
cal characteristics, for example whether they are in the chem-
ical group of “bisphosphonates” or “anthracyclines” or share
a commonmechanism of action, for example “beta-blockers”
or “glucocorticosteroids.” These grouping features are part of
the categorical information about medicines; information is
always and necessarily true for that medicine.
Example:
“Chronic treatment with a non-steroidal anti-inflam-
matory drug.”
Medications were also described and identified as a group on
the basis of their therapeutic use, for example, whether they
4 BioMed Research International
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Detailed analysis of the medication information-dosage instructions
information
Figure 3: Graph of the types of dosage information in eligibility
criteria.
are used to treat hypertension or in cancer chemotherapy.
This information is not part of categorical medicinal product
information, it is contextual, and it changes over time. For
example, for many years aspirin (acetylsalicylic acid) was
used only as an analgesic and antipyretic and then it was
discovered to have antithrombotic properties and so is now
additionally used as secondary prevention therapy after
myocardial infarction, stroke, and a variety of other cardio-
vascular events, so its therapeutic use has changed over time.
Example:
“Patients receiving antipsychotics who are not on stable
doses of atypical antipsychotics for four weeks prior to
baseline.”
Just asmedications can be described and identified as a group
according to their therapeutic use, they can also be grouped
by particularly significant nontherapeutic effects; these are
usually considered to be unwanted and undesirable and are
therefore often known as “adverse effects.” This information
is also contextual and changes over time, especially as expe-
rience with the use of the medications grows.
Example:
“Any concomitantmedication known to prolong theQT
interval.”
Medications in eligibility criteria were described and identi-
fied as a group by their authorisation status, whether or not
they have a formalmarketing authorisation.This information
is factual information about medicinal products at a point in
time within their overall development lifecycle (Figure 3).
Example:
“Treatment with a non-approved or investigational
drug within 30 days before Day 1 of study treatment.”
Dosage instructions information [14] is information about
dose quantity (individual dose quantity, daily dose quantity,
or cumulative (“lifetime”) dose quantity), about timing of
administration (frequency of individual administrations or
duration of the course of therapy or start/stop dates) and
about route of administration. Indication information is not
considered a core component of the dosage instructions
information but is assessed with them as provision of the
reason for the medication can be given as part of the instruc-
tions.
Less than 10%of themedication focused eligibility criteria
made any reference to dose quantity information and of those
half of those criteria did not specify a dose quantity per se
but specified “stable dosage” or “changing dosage” as part of
their description, implying that dose quantity would need to
be queried.
Example:
“Low dose warfarin (1mg po qd) is permitted if the
INR (international normalized ratio) is <1.5. Low dose
aspirin is permitted (≤100mg daily).”
A similarly small percentage of the eligibility criteria specif-
ically referenced one or more routes of administration for
medications directly (oral and intravenous) and further 7 cri-
teria referenced route of administration by the proxy grouper
concept of “systemic,” which implies oral or parenteral routes
of administration (as opposed to topical routes).
Example:
“Patients that required any use of IV vasodilators.”
However more than a quarter of all medication focused eli-
gibility criteria described the indication for use of the medi-
cation as part of their content.
Example:
“Patients in whom anticoagulant treatment for their
index PE or DVT should be continued.”
Almost half of medication-based eligibility criteria described
some element of the timing of the medication administration.
Of these, 73 were “within” and 11 were “prior to” a certain
point, usually a milestone in the study lifecycle, screening,
randomisation, or first dose of study medication. The others
were “for at least. . .before.”
Interestingly, some eligibility criteria, and particularly
those describing use of another investigational agent, also
stated a time period in terms of “within x days or 5 half-lives,
whichever is longer.”
Example:
“History of felbamate treatment within the past 3
months.”
5. Other Types of
Medication-Related Information
The 79 eligibility criteria that referenced medication-related
information that could possibly be included in a broad
Medication Profile were categorised as described in Figure 4.
All the eligibility criteria that described allergy or hyper-
sensitivity to a medication or an excipient were exclusion
criteria.
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Figure 4: Graph of the types of medication-related eligibility
criteria.
Example:
“History of hypersensitivity to docetaxel or polysorbate
80.”
Eligibility criteria describing adverse events to a medication
or type of medication were mostly exclusion criteria. Note
that an allergy could be considered an adverse event and also
included in this category but in this analysis was classified
separately if specifically described (as above).
Example:
“Unresolved or unstable serious adverse events from
prior adjuvant chemotherapy or radiotherapy.”
There were 12 eligibility criteria looking at current or past
substance and alcohol misuse, either directly or by referencing
screening and/or current or past smoking status and nicotine
use. Two criteria were listed as inclusion criteria, but they
specified a “negative result” which semantically means that
they were effectively exclusion criteria.
Example:
“Current alcohol dependence or drug abuse.”
All the eligibility criteria which were described in terms of
contraindications to a medication or group of medications
were exclusion criteria.
Example:
“Contraindications to the use of corticosteroid treat-
ment.”
Some eligibility criteria described the subject’s ability or
otherwise to administer/have administered the medication in
a particular formulation.
Example:
“Patients unable to swallow oral medications.”
All the eligibility criteria which described the subject being
indicated for treatment with a medication or group of medi-
cations were exclusion criteria; in these criteria the indication
for medication use is used as a proxy for a set of diagnoses.
Example:
“Indication for anticoagulant therapy for a condition
other than atrial fibrillation (e.g., VTE)” (where VTE
is venous thromboembolism).
6. Discussion
6.1. Importance of Medication Profile Information. The results
of the analysis show that just over 18% of the 1112 examined
eligibility criteria from the 41 clinical trials made reference to
medication information.This information therefore needs to
be present in a potential subject’s Medication Profile in order
to ascertain whether that person would be eligible for a study.
This proportion is approximately double the proportion of
examined eligibility criteria that referred to laboratory test
information, which provides good evidence of the value of
using a patient’s Medication Profile for protocol feasibility
studies and in the development of computer platforms and
tools to support patient recruitment.
This proportion is considerably lower than an analysis
conducted by Ross et al. [15], which found, of 1000 eligibility
criteria studied, “criteria specifying treatments or interven-
tions participant has received or will receive” accounted for
34% of the total; however no clear definition of the difference
between a “treatment” and an “intervention” is provided in
that analysis.The proportion of eligibility criteria referencing
laboratory data was also lower in the Ross analysis, 9% as
opposed to 23%; this suggests that the categorisation in this
analysis was more granular than that of Ross et al.
6.2. Current Medication and Past Medication. The analysis
shows the relatively high level of importance of a subject’s
current medication as compared to the medication history,
in that almost twice as many eligibility criteria referred to
medication administered “now” (and including prior to and
including “now”) as referred to those having been adminis-
tered in the past and are no longer being administered. Note
that in the context of eligibility criteria the “now” may well
be a specified point in the trial process, randomisation, first
administration of the investigational product, and so forth.
However, if the number of eligibility criteria that focus on
previous administration of a study agent, which is a type of
“past medication,” is included, this would give roughly equal
value to knowledge of “current” and “past” medication. This
is important because in the healthcare delivery domain the
current medication is deemed to be the more important, for
decision support, and so forth, with a longitudinal record
being of lesser importance.
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6.3. Investigational Product Use. There are a significant num-
ber of eligibility criteria that refer to previous administration
of a study agent or to the authorisation status of products that
have been previously administered, which includes use of an
authorised medication outside of its approved indications.
This is significant because in recent years there has been
a growth in the use of study registries which, accompanied
by the concentration of clinical research in a smaller number
of large centres, means that the reuse of potential subjects is
becoming a problem.
In order to correctly interrogate a Medication Profile for
use of study agents or other nonapproved drugs, it has to be
possible to identify these. There are two possibilities. One is
to incorporate the use of a medicines knowledge base that
has wide coverage of study agents as part of the query appli-
cation (see below) that could be used to compare all the
medicines in a patient’s profile with their authorisation sta-
tus in the country of use. Unfortunately, most medicines
knowledge bases do not have full coverage of investigational
agents because information about these is notwidely available
and putting such information, even in a limited way, has
sometimes been deemed “advertising,” which is not per-
mitted for unauthorised medicines. Even though there is a
move from the regulatory agencies to increase the availability
of information on investigational products and an acceptance
that inclusion of basic information about an unlicensed
product in a knowledge base is not “advertising,” it is likely
to be some several years before such information is widely
available and is useable in a computable way. Even if the
information was available, the comparison of each and every
medicine in a profile against an authorisation status is a
considerable task, especially for protocol feasibility testing
when a large volume of potential patients’ information is
being queried.The second possibility, therefore, is to indicate
directly into the Medication Profile when a patient is taking
an investigational agent. This is not, to the writer’s under-
standing, currently done in any formalway by anymedication
recording system (PMR or EHR) used in direct patient care
but on the evidence of this analysis would appear to be useful.
6.4. Identifying Medicines—Knowledge Base Requirement.
Only a very small number, less than 3%, of eligibility criteria
that focus on the subject’s use of medicines directly describe
the medicines themselves; all the rest describe medicines in
groups, either by categorical characteristics or by therapeutic
use, or indeed by nontherapeutic effect.
This is significant for any process that wishes to use
Medication Profile information in protocol feasibility studies
and/or in tooling to support patient recruitment in that it
introduces a requirement for knowledge about medicines to
be available for use. A medicines knowledge base, such as
those produced to support medication decision support in
direct to patient care, should have the categorical information
and the therapeutic use information readily available and in
a format that would be straightforward to process to provide
the additional information to support the querying of these
eligibility criteria [16]. A knowledge base of this type will
use the Summary of Product Characteristics (SmPC) as one
of its primary sources. In that document, which is laid out
in standard sections [17], the categorical characteristics of a
medicine are described in the “pharmacodynamic properties”
section (section 5.1 of an SmPC) usually a direct reference to
a formal characteristics classification such as the ATC [18].
Therapeutic use is similarly described in the “therapeutic
indications” section (section 4.1 of an SmPC).
However, although nontherapeutic effect information
of the types seen in the eligibility criteria is available for
medicinal products as part of this authorisation information,
it is not as organised and as accessible as the categorical char-
acteristics or indications information nor is it standardised.
For although there is a section in an SmPC labelled “unde-
sirable effects” (section 4.8 of an SmPC) this merely lists all
unwanted effects that themedication has been found to cause
or suspected of causing. For newermedicines these effects are
at least grouped together in categories based on theMedDRA
“System Organ Class” [19] hierarchy and therefore it is pos-
sible tomore easily identify those of relevance to an eligibility
criteria, say, by looking at the cardiac disorders for QT
interval prolongation. But this type of adverse effect informa-
tion may also or alternatively be described elsewhere, as in
the “special warnings and precautions for use” [20] section
(section 4.4 of an SmPC).
Information about enzyme modulation caused by a
medicinal product may be even more dispersed in a single
SmPC. It may appear in the “posology andmethod of admin-
istration” section (section 4.2 of an SmPC) because it is seen
as a requirement for dosage adjustment; or it may appear
in the “special warnings and precautions for use” part
(section 4.4 of an SmPC) as information about coadmin-
istration and it will almost certainly also appear (again) in
the “interaction with other medicinal products and other
forms of interaction” (section 4.5 of an SmPC). Therefore,
although the raw data is usually available, even if somewhat
scattered in location, this has not be processed into useful
knowledge for use in practice. For example, there is no well
documented and agreed set of medicines acknowledged as
those which prolong the QT interval in a clinically relevant
manner. An illustration of this is that the British National
Formulary lists QT interval prolongation as side effect of
macrolide antibiotics [21] but does not do so for quinolone
antibiotics although such effects have been documented [22]
and indeed are noted in SmPC [20]. The same is true for
cytochrome P450 isoenzyme modulators and indeed is more
complicated as there are several individual isoenzymes to
consider. Knowledge bases currently take this raw data on
enzyme modulation and apply it in the maintenance of their
drug interaction applications, rather than provide it directly
as information about the medicinal products that are CYP
modulators [23]. Recognising this issue, some clinical trial
protocols will document lists of medications that in their
context are considered to carry these risks, for example, “any
concomitant medications that may cause QTc prolongation
or induce Torsades de Pointes (see the Appendix for the list
ofmedications in Tables 1 and 2) or induceCYP3A4 function”
and “concomitant use of CYP3A4 inhiibitors or inducers. See
Section 5.3.2 for list of prohibited medications.” But these are
not standard lists and have to bemanaged on a study by study
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Table 1: Results summary: eligibility criteria containing medication
information.
Eligibility criteria making
direct reference to medication
information
201 (18.1%) 178 exclusion33 inclusion
Current medication use 71 (35.3%) 68 exclusion3 inclusion
Prior study medication 45 (22.4%) 30 exclusion15 inclusion
Diagnosis with medication
use qualifier 37 (18.4%)
26 exclusion
11 inclusion
Other study participation 38 (18.9%) 35 exclusion3 inclusion
Treatment failure 10 (5.0%) 9 exclusion1 inclusion
Table 2: Results summary: identifying medicines in the medication
information in eligibility criteria.
Medicines specifically named 10 (5.0%)
Identified by categorical characteristics (e.g.,
chemical group) 69 (34.3%)
Identified by therapeutic use 69 (34.3%)
Identified by nontherapeutic effects (e.g., adverse
events caused) 34 (16.9%)
Identified by authorisation status 19 (9.5%)
basis and cannot necessarily be applied to other studies that
have not provided such information.
There were a small number of eligibility criteria that
described alcohol and/or substance misuse and/or nicotine
use. Whilst not directly part of the Medication Profile, there
is information that could contribute to this.Medications used
specifically in the management of substance misuse, alcohol
misuse, and nicotine replacement therapy are likely to be
documented in a profile and, by using a knowledge base to
identify these and then querying against that set, some assess-
ment of a potential subject’s suitability against this type of eli-
gibility criteria could bemade using information in theMedi-
cation Profile.
A knowledge base could be used to provide information
to assist in querying for the small number of eligibility criteria
that reference contraindications to medications, by listing
these contraindications as conditions and then the patient
record querying for evidence of their presence directly.
However, this is a considerable amount of processing for a
relatively small number of eligibility criteria; it would be
more constructive to protocol feasibility studies and patient
recruitment support to list the conditions themselves, rather
than use a medication’s contraindications as a proxy.
6.5. Dosage Instructions. The proportion of eligibility criteria
that describe use of medicines and that also referenced
dosage instruction information showed some clear patterns.
Less than 10% described either dose quantity, frequency
of administration, or duration of the course of therapy,
and a similar proportion described route of administration.
However, nearly half of all eligibility criteria that describe
use of medicines also reference when the course of therapy
occurred, either that it was currently in progress or how long
in the past it had occurred and ceased, as already described
in the classification of those eligibility criteria that reference
either current medication or past medication.
Given the complexity that can easily develop in describing
dosage instructions information in a machine readable way,
these results indicate that there is little value to be obtained by
attempting complex querying of this information within the
Medication Profile for protocol feasibility studies and patient
recruitment tooling. But the results show that it is important
for protocol feasibility studies andpatient recruitment tooling
to be able to ascertain the basic timing of the course of ther-
apy (i.e., start and stop dates), even if the detail of the dose
quantity, frequency of administration, or route of adminis-
tration within that course is not provided in any machine
readable/queryable way.
6.6. Indication for Treatment and “Reason to Stop”. 30% of
eligibility criteria that include medicinal product use also
require evaluation of the indication for the use of the medi-
cation, but this information is rarely directly recorded in a
Medication Profile and therefore is presently unlikely to be
directly available in a clinical data warehouse or EHR system.
The information may well be present implicitly; the
patient was diagnosed with breast cancer at point X and three
weeks later doxorubicin is administered; it is almost certain
that the doxorubicin would be indicated for the treatment of
the breast cancer. So whilst a clinician reviewing a patient
with a complete health record can make that connection
straightforwardly, an application querying a clinical data
warehouse or EHR system would find that an extremely
complex task to accomplish successfully given the current
state of such systems. And even a clinician may find this
type of inference difficult for thosemedications with a diverse
set of therapeutic uses; being clear of the indication for
the use of amitriptyline, whose primary use has been as an
antidepressant but is now as likely to be used as an analgesic in
postherpetic neuralgia or as a prophylactic against migraine,
is a much more tricky task.
Note that indication information in an eligibility criterion
is subtly different from the combination of a particular diag-
nosis with a medication qualifier, although each describes
a medication and a condition/symptom being treated. The
latter is somewhat easier to query for in a clinical data ware-
house or EHR system; the diagnosis can be queried directly,
and if found, then the qualifying medication can be investi-
gated, again directly. Since bothmechanisms achieve roughly
the same ends, potential subjects with a particular diagnosis
also taking a particularmedication that is related to that diag-
nosis, wording eligibility criteria in the pattern of “diagnosis
+medication qualifier” is likely to bemore efficient for query-
ing in protocol feasibility studies and patient recruitment
tooling than using the “medication and indication” pattern.
A small number of eligibility criteria referred directly to
treatment failure; the subject had therapy with the particular
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medication, but it was unsuccessful. In addition, in the anal-
ysis of those criteria which were deemed as not being directly
related to the Medication Profile but referenced medication
in some way, the majority concerned allergy/hypersensitivity
or an adverse event. If these are considered together as “rea-
son(s) to stop” a therapy, this amounts to significant number
of the eligibility criteria. “Reason to stop” information is
rarely recorded directly, but these results suggest that it would
be of use if it were.
Currently, there is nothing formally available that would
provide information to support a query for the very small
number of eligibility criteria that are concerning a potential
subject’s ability to self-administer particular formulations of
a study agent. This type of information is more likely to be
recorded in nursing and care notes than in any other part of
a patient’s health record.
6.7. Ethical and Medicolegal Implications. This analysis of
eligibility criteria requirements for the Medication Profile
has focused on the medication specific data elements that
the profile would need to contain in order to support the
systems mediated detection of suitable subjects for protocol
feasibility testing and patient recruitment. However, in order
for these data to be actually used in such testing or going
forward as part of a clinical trial data set, it would be neces-
sary to comply with all the appropriate ethical and medico-
legal requirements, including those of Good Clinical Prac-
tice (GCP) [24]. These include the requirement that the
authorship and time stamping of all data are preserved and
that all changes are made in a version controlled manner
permitting full traceability and the potential for rollback to
a prior version of the data, a comprehensive audit trail and a
long-term commitment to data retention.Many of these GCP
medicolegal requirements are identical or very similar to the
medicolegal requirements for electronic health record data,
such as those published in ISO 18308:2011 “Requirements for
an electronic health record architecture” [25].
7. Conclusion and Recommendations
Information from a potential subject’s Medication Profile
makes a significant contribution to the overall set of queries,
based on study eligibility criteria, which are used in protocol
feasibility studies and patient recruitment tooling.
Information on both current medication use and past
medication use was shown to be equally useful, when use of
a past study agent is included as a type of past medication,
which supports the requirement to have longitudinal infor-
mation in a Medication Profile as well as current medication
information.
In terms of the detail of what is recorded in the profile
in addition to the identification of the medicinal products
themselves, the most useful element is the timing of the
course of therapy, when it commenced and if/when it has
ceased. Other dosage information, including route of admin-
istration and dose quantity, was found to have limited use. In
conjunction with the start and stop timing, direct recording
of information about the indication to start a therapy and
reasons for its cessation were found to be of benefit in this
context. Neither is currently recorded in routine practice.
The analysis demonstrated the requirement to be able to
query a Medication Profile to ascertain whether any of the
medications that a patient has received is an “investigational
agent” (i.e., a medication which does not possess a marketing
authorisation and therefore is administered as part of formal
clinical research).
It was clear that, due to the way eligibility criteria are
currently written, a medicines knowledge base is required to
expand some grouping concepts from the criteria into indi-
vidual medication concepts such that the Medication Profile
can be queried directly. In addition, it is recommended
that further work be undertaken in this context to produce
standard and agreed sets of medications acknowledged to
cause particular nontherapeutic effects that are known to be
of concern in clinical trials, most particularly thosemedicinal
products that prolong the QT interval and those that cause
CYP modulation.This would have value in the wider context
of clinical decision support as well as for study design and
execution.
It was interesting to note the similarities and differences
between two particular patterns of eligibility criteria, the
“diagnosis + medication qualifier” pattern and the “medica-
tion + indication” pattern. Given the known lack of recording
of indication information, the former pattern appears to
be the more useful; yet the latter pattern appears to have
more extensive use in eligibility criteria. Further investigation
in this area could be undertaken to further explore the
similarities and differences, and if there was evidence that
the one pattern was significantly more effective in protocol
feasibility studies and patient recruitment tooling, this should
be reflected back to those working in study design. It should
be noted that optimisation of the eligibility criteria given in a
study protocol would be expected to optimise recruitment of
subjects to that study, so this would indeed be a useful area
for further work.
This study examined just over a thousand eligibility crite-
ria from 41 phase III studies into new medications; a similar
type of investigation could be conducted on other study
phases and study types. This should include observational
(phase IV) studies for medications and studies into other
types of medical intervention (procedures and device use)
to confirm if similar patterns of information requirements
exist or indeedwhether these types of studies place additional
requirements for information on the Medication Profile.
The results of this analysis give several recommendations,
beyond the provision of requirements for the content of a
Medication Profile. These recommendations are primarily
aimed at authors of eligibility criteria but also to authors of
medicines knowledge bases and to the providers of electronic
health record systems. Medication Profile information in
EHR systems should be structured and designed such that
their recording of medication information and in particular
the granularity of the data elements within that support all of
the relevant use cases for that information: high quality direct
care delivery and also secondary uses, including clinical
research.
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Table 3: Results summary: identifying dosage instructions informa-
tion in eligibility criteria.
Dose quantity 19 (9.5%)
Route of administration or “proxy” 27 (13.4%)
Indication for use 62 (30.8%)
Timing information 94 (46.8%)
If an eligibility criterion needs to identify subjects using a
medication to treat a particular condition, rather than stating
the medication and indication (medicine X to treat condition
Y), based on this analysis it is more useful to state a “diagnosis
Y and treatment with X,” as a diagnosis and a medication are
much more likely to be separately present and queryable in a
health record than the medication with its indication for use.
Standardised sets of the medications that are acknowl-
edged to cause important clinical effects such as prolongation
of the QT interval and CYPmodulation should be developed.
These should be agreed for use in both direct to patient
healthcare and clinical research and should be available for
use in knowledge base systems.
In the interim, when an eligibility criterion refers to such
an effect, it should provide the set of medications that the
author deems to be causative, to avoid different investigators
using different sets.
These conclusions and recommendations will be com-
bined with other recommendations and requirements from
the analysis of other uses andprocesses for patientmedication
information and will be used to develop the specification for
a cohesive and comprehensive Medication Profile which will
be published later.
Appendix
Results Summary Tables
See Tables 1, 2, and 3.
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